To determine the impact of mbIL-6R blockade on IL-6-related T cell phenotypes in vivo, we analyzed data from the EXTEND clinical trial, which investigated the impact of tocilizumab, a monoclonal antibody targeting global IL-6 signaling by blocking both mbIL-6R and soluble IL-6R, on beta cell loss in pediatric patients with new onset T1D (29). Here, IL6 is linked to type 1 diabetes mellitus.